Coronary disease & ACS

Intravascular Imaging vs Angiography Guidance for Percutaneous Coronary Intervention (PCI) of Severely Calcified Lesions: The ECLIPSE Trial

JACC Cardiovasc IntervPublished Secondary analysis of the ECLIPSE randomised trial

Primary result · TVF (Kaplan-Meier estimate)Result — go to the resultAdjusted hazard ratio 0.74 95% CI 0.56–0.97

Authors' conclusion

IVI guidance during PCI of severely calcified lesions was associated with improved 1-year clinical outcomes compared with angiographic guidance alone, whether OA or BA was used for vessel preparation prior to drug-eluting stent placement.

Study context

Population
Patients undergoing PCI of severely calcified lesions, randomised to orbital atherectomy vs balloon angioplasty before drug-eluting stent
Participants
2,005 patients
Comparison
Intravascular imaging (IVI) guidance vs angiographic guidance alone during PCI
  • IVIn = 1,246
  • Angiographic guidance alonen = 759reference
Primary endpoint
Target vessel failure (TVF)
Follow-up
1 year
Methodological detailsIVI at operator discretion, Median follow-up 365 days (Q1-Q3: 365-365 days)
  • IVI at operator discretion
  • Median follow-up 365 days (Q1-Q3: 365-365 days)

Primary result

TVF (Kaplan-Meier estimate)

Adjusted hazard ratio

0.74

95% CI 0.56–0.97

P = 0.03

By group

IVI vs Angiographic guidance alone
adjusted HR 0.74 (95% CI 0.56–0.97); P = 0.03

As reported in the abstract

Further findings

OutcomeOCTIVUSAdjusted HR (95% CI)P value
TVF, OCT vs IVUS guidance · 1 year7.7%12.2%0.78 (0.52–1.18)P = 0.24

Target vessel failure (TVF), IVI effect by randomised orbital atherectomy (OA) vs balloon angioplasty (BA) (subgroup)

Effect of IVI guidance consistent in OA and BA
  • Interaction P = 0.48

Original publication

Intravascular Imaging vs Angiography Guidance for PCI of Severely Calcified Lesions: The ECLIPSE Trial. JACC Cardiovasc Interv. Published 13 October 2025. doi:10.1016/j.jcin.2025.08.024

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.